Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03731715
Other study ID # YKP509C001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 7, 2019
Est. completion date June 29, 2022

Study information

Verified date May 2023
Source SK Life Science, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a Screening Period of up to 28 days and a Treatment Period of 87 days.


Description:

A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (≥18 years), Cohort II (12 to <18 years), Cohort III (6 to <12 years), and Cohort IV (2 to <6 years). For Cohorts I and II, PK assessments of carisbamate, S-enantiomer and its R-enantiomer plasma concentrations, will be conducted on Days 1, 2 and 3 of the single dose period at pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours after dosing and on Day 17 of the multiple-dose period at pre dose and 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours after dosing; trough samples will be collected on Days 45 and 73 of the dose-adjustment period. For Cohort III, PK assessments of carisbamate, S-enantiomer and its R-enantiomer plasma concentrations will be conducted on Days 1, 2 and 3 of the single dose period at pre dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours after dosing and on Day 17 of the multiple-dose period at pre-dose and 2 hours after dosing; trough samples will be collected on Days 45 and 73 of the dose-adjustment period. For Cohort IV, a sparse PK sampling approach will be used, and the time of PK sampling time will be based on the PK results from the other cohorts. A maximum of 2 to 4 time points on each day (1 and 17) will be collected. Safety assessments include adverse event (AE) and concomitant medication reporting, clinical laboratory testing, vital sign measurements, 12 lead electrocardiograms (ECGs), physical examinations, and neurologic examinations.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date June 29, 2022
Est. primary completion date May 23, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of LGS as evidenced by the following: 1. More than 1 type of generalized seizure, including drop seizures (atonic, tonic, or myoclonic), for =6 months before Visit 1 2. Previous electroencephalogram reporting diagnostic criteria for LGS (abnormal background activity accompanied by slow spike-and-wave pattern <2.5 Hz) 2. Male or female aged =2 years at the time of consent 3. Aged <11 years at the onset of LGS 4. Written informed consent signed by the subject or legal guardian prior to entering the study in accordance with the ICH GCP guidelines. Age appropriate assent will be obtained for children and adolescents. If the written informed consent is provided by the legal guardian because the subject is unable to do so, a written or verbal assent from the subject must also be obtained. 5. Receiving 1 to 3 concomitant AEDs at a stable dose for =30 days before Visit 1 (vagal nerve stimulation [VNS] and ketogenic diet, stable and ongoing for =30 days before Visit 1, do not count as AEDs) 6. In the Investigator's opinion, parents or caregivers must be able to report accurate seizure assessments during the screening and study periods and subjects must be able to ingest study drug 7. Body weight =8 kg for subjects enrolled in Cohort IV 8. Subjects with an implanted vagal nerve stimulator will be allowed if the vagal nerve stimulator was implanted at least 5 months prior to Visit 1 (Screening) and the stimulator parameters are not changed for 30 days prior to Visit 1 and for the duration of the study 9. Subjects following a ketogenic diet will be allowed as long as the diet has been stable for at least 30 days prior to Visit 1 (Screening) and will remain stable for the duration of the study. Exclusion Criteria: 1. Progressive neurological disease 2. Prior treatment with carisbamate 3. Evidence of clinically significant disease or any medical condition that would compromise the subject's ability to safely complete the study 4. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the investigational medicine product 5. Acute disease state (e.g., nausea, vomiting, fever, or diarrhea) within 7 days before Day 1 6. Scheduled for surgery during the study 7. Ketogenic diet or VNS, unless stable and ongoing for =30 days before Visit 1 8. Treatment with an investigational drug or device =30 days before Visit 1 9. Status epilepticus within 12 weeks of Visit 1 10. Felbamate for <1 year (subjects taking felbamate for =1 year must have a stable dose for 60 days before Visit 1) 11. Concomitant use of vigabatrin or other medications known to be inducers of CYP3A 12. Use of drugs known as UGT inducers, e.g., carbamazepine, phenytoin, phenobarbital, primidone, or oxcarbazepine 13. Use of cannabinoids (any form), cannabidiols, or medical or recreational marijuana 14. Use of any prescription or non-prescription drugs, including over-the-counter medication, non-routine vitamins and herbal products within 2 weeks prior to study drug administration unless discussed and agreed with the Sponsor's medical representative in writing. (Medication used to treat TEAEs does not lead to a compulsory exclusion of subjects.) 15. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours before Day 1 and until the end of each PK sampling period 16. Consumption of grapefruit or grapefruit-containing products within 72 hours before Day 1 and until the end of each PK sampling period 17. History of any serious drug-induced hypersensitivity reaction (including but not limited to Stevens Johnson syndrome, toxic epidermal necrolysis, Drug Rash with Eosinophilia and Systemic Symptoms [DRESS]) or any drug-related rash requiring hospitalization 18. History of AED-associated rash that involved conjunctiva or mucosae 19. History of more than one non-serious drug-related hypersensitivity reaction that required discontinuation of the medication 20. Significant clinical laboratory abnormalities, including elevation of serum AST or ALT more than 1.5 times ULN for age group, or any elevation of bilirubin or creatinine about the ULN for age group at Screening 21. Any clinically-significant uncontrolled medical illness, including hepatic or renal failure, ischemic disease, human immunodeficiency virus (HIV) infection, active sexually-transmitted disease (STD), active viral hepatitis, malignancy, or any disorder that in the judgement of the investigator places the subject at risk by participation in this study 22. History of drug-induced liver injury 23. Positive urine screen of drugs of abuse (if not due to concomitant medication, e.g. benzodiazepines as hypnotics) for adult and adolescent subjects. 24. Adrenocorticotropic hormone within the 6 months before Visit 1 25. History of anoxic episodes requiring resuscitation within 6 months before Visit 1, drug or alcohol dependency or abuse within approximately the last 2 years, or use of illegal recreational drugs 26. Females who are breastfeeding or pregnant at Screening or Baseline or who are of reproductive age and do not agree to be abstinent or to use highly effective contraception 27. Intermittent use of benzodiazepine of >4 single administrations in the month before Visit 1 28. Clinically significant abnormality on the 12-lead ECG at Screening, and any child or adolescent with a QTcF less than 330 ms or greater than 450 ms 29. Congenital short QT syndrome 30. Hypersensitivity to the study drug or any of the excipients 31. Psychotic disorder(s) or unstable recurrent affective disorder(s)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carisbamate
An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Locations

Country Name City State
United States Johns Hopkins Hospital Baltimore Maryland
United States Duke Health Durham North Carolina
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States UW Valley Medical Center Renton Washington
United States The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center) Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
SK Life Science, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The area under the curve (AUC) of carisbamate after a single and multiple doses of carisbamate. Safety Assessment Days 1-3, Day 17
Primary The maximum plasma concentration (Cmax) after a single and multiple doses of carisbamate. Safety assessment Days 1-3, Day 17
Secondary Safety - adverse events (AEs) reporting after a single and multiple doses of carisbamate. Adverse event assessment for seriousness (yes, no), severity (mild, moderate, severe), affect on carisbamate dosing (increase, reduced, interrupted, withdrawn, no change), and outcome (recovered/resolved,recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, fatal or unknown). Days 1-87
See also
  Status Clinical Trial Phase
Withdrawn NCT02910297 - The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
Recruiting NCT05339126 - RNS System LGS Feasibility Study Phase 2
Active, not recruiting NCT03355209 - A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome Phase 3
Completed NCT04062981 - Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome Phase 1
Not yet recruiting NCT05066217 - EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox Gastaut Syndrome Phase 2
Recruiting NCT04611438 - Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome Phase 3
Completed NCT05364021 - Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies Phase 1/Phase 2
Terminated NCT03955432 - Long-term Cardiac Monitoring in Epilepsy N/A
Completed NCT02224560 - Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults Phase 3
Not yet recruiting NCT06464653 - Forel's Field Electrical Stimulation for Lennox-Gastaut Syndrome N/A
Not yet recruiting NCT05485831 - Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY
Active, not recruiting NCT05044819 - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Phase 4
Not yet recruiting NCT05374824 - Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
Active, not recruiting NCT02655198 - Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy Phase 2
Completed NCT03467113 - A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol Phase 1
Recruiting NCT05219617 - Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults Phase 3
Active, not recruiting NCT03936777 - A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome Phase 3
Available NCT03778424 - An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
Available NCT02307578 - An Extended Access Program (EAP) for Perampanel
Available NCT06149663 - Intermediate-Size Expanded Access Protocol (EAP) for LP352